The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 14 of the 38 sources its claims cite were checked for support.
Abstract
Background: The rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates effective therapies. This meta-analysis therefore assesses the efficacy of omega-3 PUFAs in reducing triglycerides in MASLD patients and examines how diabetes status modulates this effect. Purpose: To resolve existing uncertainties, this systematic review and meta-analysis was conducted to evaluate the efficacy of omega-3 PUFAs in reducing TG among MASLD patients, with a prespecified analysis to elucidate the role of diabetes status. Patients and Methods: We systematically searched PubMed, Web of Science, Embase, and the Cochrane Library (up to Sep 22, 2025) for randomized controlled trials assessing omega-3 PUFA supplementation on triglyceride levels in MASLD patients, with subgroup analysis by diabetes status. Results: Pooled data from 9 studies (n=528) revealed that omega-3 PUFA supplementation was associated with a significant reduction in triglyceride (TG) levels in MASLD patients (MD: -13.81 mg/dL; 95% CI: -24.56, -3.06); however, considerable heterogeneity (I²=22.5%) suggests that the true effect may be inconsistent across different patient populations. Subgroup analysis delineated a stark contrast: while a beneficial effect was confirmed in non-diabetic MASLD patients (MD: -15.78 mg/dL), it was absent in those with comorbid type 2 diabetes (P = 0.33). Meta-regression further confirmed that the prevalence of diabetes within study populations did not linearly influence the TG-lowering outcome (P = 0.752). Finally, the intervention showed no significant impact on other metabolic parameters such as ALT, HDL, or LDL. Conclusion: This meta-analysis suggests that omega-3 fatty acids are associated with reduced TG levels in MASLD patients on average, but the effect is inconsistent and influenced by diabetes status. The non-significant effect in diabetic patients and the wide prediction intervals call for caution in interpreting these findings, and further research is needed to identify subgroups that may benefit.
Overview
CoChat Summary
## TL;DR
This meta-analysis of 9 randomized controlled trials (n=528) found that omega-3 PUFA supplementation was associated with a modest reduction in triglycerides in patients with MASLD overall (MD −13.81 mg/dL). The benefit was seen in non-diabetic patients but not in patients with type 2 diabetes, and no significant effects were found for ALT, HDL, or LDL.
## Key findings
- Across 9 RCTs including 528 participants, omega-3 supplementation reduced triglycerides in MASLD overall by MD −13.81 mg/dL (95% CI −24.56 to −3.06), with I² = 22.5%.
- In the non-diabetic subgroup (4 studies, n=214), triglycerides decreased by MD −15.78 mg/dL (95% CI −27.25 to −4.31).
- In the diabetic subgroup (2 studies, n=97), the triglyceride effect was not significant (MD −16.71 mg/dL, 95% CI −50.28 to 16.85; P = 0.33).
- Meta-regression found that the proportion of diabetic patients did not explain heterogeneity in triglyceride response (regression coefficient = 15.703; P = 0.752; R² ≈ 0%).
- Omega-3 had no significant impact on other metabolic indicators: ALT (7 studies, 428 participants; MD −1.44 IU/L), HDL (7 studies, 454 participants; MD −0.06 mg/dL), or LDL (7 studies, 452 participants; MD 0.26 mg/dL).
## Methods
- Systematic review and meta-analysis of randomized controlled trials of omega-3 PUFA supplementation in adult MASLD patients, with prespecified subgroup analysis by diabetes status.
- Searched PubMed, Web of Science, Embase, and the Cochrane Library through September 22, 2025; the review followed PRISMA and was registered in PROSPERO (CRD420251160035).
- Primary analysis used random-effects meta-analysis of mean differences (MDs) with 95% CIs; heterogeneity was assessed with I² and Cochran’s Q, and meta-regression tested whether diabetes prevalence modified the effect.
## Limitations
- The paper states that the number of included studies was limited, especially in the diabetes subgroup, which may have reduced statistical power.
- The paper states there was heterogeneity across studies in omega-3 dosage, treatment duration, and patient characteristics, leaving possible residual confounding despite random-effects modeling and meta-regression.
- The paper states that outcomes were mainly laboratory markers rather than clinical endpoints such as liver fibrosis progression or cardiovascular events, so long-term benefits remain uncertain.
- Evident from the text: the diabetic subgroup was very small (2 studies, n=97), and the review did not assess publication bias because the number of studies was too limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
11 Valid · 2 Not valid · 9 Not checked · 23 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, prior studies suggest that the beneficial effects of omega-3 on liver enzymes may require longer treatment durations to manifest,47 and the average treatment duration in the trials included in this study may have been insufficient to capture such changes.”
§ The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status > Discussion > Interpretation of Results and Discussion of Mechanisms
What the sources say
- Disputedcites [47] Parker, 2012, J Hepatol sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) says changes in liver enzymes were not a function of supplementation duration: 12-month studies showed similar or smaller changes than shorter studies. The Results report a median treatment duration of six months, but the paper does not suggest that longer treatment was needed for liver-enzyme benefits to emerge. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“The accumulation of TG in hepatocytes, stemming from disrupted lipid homeostasis, forms the basis of MASLD patholog.6,7”
§ The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status > Introduction
What the sources say
- Supportedcites [6] Ipsen, 2018, Cell Mol Life Sci source
The Introduction states that disruption of hepatic lipid-homeostasis pathways can cause fat retention and NAFLD, and that accumulation occurs when lipid acquisition exceeds disposal. The Lipid export section specifically discusses hepatic triglyceride accumulation and steatosis. The paper uses the older term NAFLD rather than MASLD. (LLM, conf=0.90)
- Supportedcites [7] Friedman, 2018, Nat Med source
In Pathogenesis > Fates of fatty acids in the liver, the paper says triglycerides that are not exported form lipid droplets in hepatocytes, a defining feature of NAFLD. The Pathogenesis section links excess fatty-acid supply or impaired disposal to the disease’s metabolic mechanisms. The paper uses the older term NAFLD rather than MASLD. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Specifically, n-3 PUFAs act as potent ligands for PPARα, triggering its activation and the subsequent upregulation of genes involved in fatty acid oxidation.32,33”
§ The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status > Discussion > Interpretation of Results and Discussion of Mechanisms
What the sources say
- Not checked — no full text of the sourcecites [32] Marx, 2004, Circ Res source
- Could not verifycites [33] Tetri, 2008, Am J Physiol Gastr Liver Physiol sourceExperimental — accuracy not yet measured
The Discussion describes liver injury associated with trans fats, not n-3 PUFA activation of PPARα. A reference title mentions PPARα-dependent hepatic lipid turnover, but the paper’s text does not address n-3 PUFAs as PPARα ligands or their upregulation of fatty-acid-oxidation genes (searched those terms and paraphrases). (LLM, conf=0.76)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, the effects of omega-3 on HDL and LDL may be influenced by numerous factors, such as the different types of omega-3 supplements used and the varying types of control groups employed.48”
§ The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status > Discussion > Interpretation of Results and Discussion of Mechanisms
What the sources say
- Supportedcites [48] Khorshidi, 2023, Nutr J source
The Discussion proposes that differences in omega-3 supplement types and oils used in control groups may have influenced the meta-analysis results. It makes this point while discussing the lack of significant effects on HDL and LDL in children and adolescents, matching the citing sentence’s cautious wording. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in diabetic MASLD patients, severe insulin resistance, chronic inflammation, and oxidative stress may impair these pathways, leading to the failure of omega-3 therapy.39”
§ The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Meta-Analysis of Randomized Controlled Trials with Subgroup Analysis by Diabetes Status > Discussion > Interpretation of Results and Discussion of Mechanisms
What the sources say
- Partly supportedcites [39] Lepretti, 2018, Nutrients sourceExperimental — accuracy not yet measured
Section 5 describes omega-3’s triglyceride-lowering and anti-inflammatory effects, while Sections 1 and 8 link insulin resistance with inflammation and oxidative stress. The paper does not say that these conditions impair omega-3’s triglyceride-lowering pathways or cause therapy to fail in diabetic MASLD patients. Its report of no insulin-sensitivity benefit in some human intervention studies concerns a different outcome. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
18 more claims · 1 with their cited sources checked
Create a free account to see all 45 claims and to verify the 5 references still open.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 18
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“7,8 Omega-3 polyunsaturated fatty acids (PUFAs) are compelling candidates for MASLD treatment due to their targeted mechanisms, including promoting fatty acid oxidation through Peroxisome Proliferator–Activated Receptor Alpha (PPARα) activation and inhibiting lipogenesis by suppressing Sterol…”
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 2×
“6,7 These lipids are not inert; through lipotoxicity, they transmit cellular stress and inflammation, thereby driving the progression of more severe diseases.”
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 1×
“2,3 This manuscript adopts the MASLD nomenclature in alignment with this current international consensus.”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“Prediction intervals were computed based on the method described by Riley 2011, 19 incorporating both the estimated between-study variance (τ²) and the uncertainty in the pooled effect estimate.”
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“However, our meta-regression explicitly demonstrated that the proportion of diabetic patients was not a significant effect modifier, offering a new perspective for understanding the heterogeneity observed in previous meta-analyses.”
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471 · cited 2×
“6,7 These lipids are not inert; through lipotoxicity, they transmit cellular stress and inflammation, thereby driving the progression of more severe diseases.”
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569 · cited 1×
“46 Furthermore, prior studies suggest that the beneficial effects of omega-3 on liver enzymes may require longer treatment durations to manifest, 47 and the average treatment duration in the trials included in this study may have been insufficient to capture such changes.”
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 521
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501 · cited 2×
“This review found that although omega-3 supplementation was associated with reduced triglyceride levels in the overall MASLD population, the wide 95% prediction intervals spanning the zero effect line preclude definitive conclusions regarding its efficacy in future clinical settings.”
InfluentialXu, J., Nakamura, M. T., Cho, H. P., & Clarke, S. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23577 · Cited by 499
N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
Jump, D. B. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf6a · Cited by 443
Why do omega-3 fatty acids lower serum triglycerides?
Harris, W. S., & Bulchandani, D. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236363.63840.16 · Cited by 398 · cited 1×
“Their lipid-lowering effects primarily target the triglyceride metabolic pathway, including promoting fatty acid oxidation and reducing lipogenesis by activating PPAR-α and inhibiting SREBP-1c, 42,43 while exerting weaker direct effects on cholesterol reverse transport and synthesis.”
Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390 · cited 1×
“13,14 Patients with both MASLD and T2DM exhibit a more severe disease phenotype and pronounced insulin resistance, which may fundamentally alter their response to PUFAinterventions.”
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Tetri, L. H., Basaranoglu, M., Brunt, E. M., Yerian, L. M., & Neuschwander-Tetri, B. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90272.2008 · Cited by 378
Kim, H.-J., Takahashi, M., & Ezaki, O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25892 · Cited by 377
Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease
Scorletti, E., & Byrne, C. D. (2013) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161230 · Cited by 326
Dentin, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25256 · Cited by 315 · cited 1×
“The moderate overall reduction in triglycerides observed in our analysis aligns with the 2021 meta-analysis, which reported a similar effect size (MD: −28.57 mg/dL) across a broader MASLD cohort.”
InfluentialSanyal, A. J., Abdelmalek, M. F., Suzuki, A., Cummings, O. W., & Chojkier, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.046 · Cited by 309
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease
Spadaro, L., Magliocco, O., Spampinato, D., Piro, S., Oliveri, C., Alagona, C., Papa, G., Rabuazzo, A. M., & Purrello, F. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.003 · Cited by 293
Wei, M. Y., & Jacobson, T. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0210-3 · Cited by 284 · cited 1×
“44,45 ALT levels exhibit spontaneous fluctuations and may not respond significantly to short-term intervention.”
Lepretti, M., Martucciello, S., Burgos Aceves, M., Putti, R., & Lionetti, L. (2018) · Nutrients · doi:10.3390/nu10030350 · Cited by 232 · cited 1×
“39 The use of n-3 PUFA may also result in the failure of beneficial effects by activating PPARα, increasing oxidative stress, and thereby enhancing hepatic mitochondrial fatty acid oxidation.”
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Anti‐obesity effects of long‐chain omega‐3 polyunsaturated fatty acids
Buckley, J. D., & Howe, P. R. C. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00584.x · Cited by 213 · cited 1×
“29 However, our study extends this understanding by specifically examining the role of diabetic status as a potential effect modifier—an aspect not thoroughly investigated in prior syntheses.”
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199 · cited 1×
“15 Filling this gap is crucial for determining whether diabetic status is a key effect modifier, thereby explaining inconsistent results in the literature and advancing toward more personalized therapeutic approaches.”
Dasarathy, S., Dasarathy, J., Khiyami, A., Yerian, L., Hawkins, C., Sargent, R., & McCullough, A. J. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000099 · Cited by 163
Botolin, D., Wang, Y., Christian, B., & Jump, D. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500365-jlr200 · Cited by 162
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142 · cited 1×
“9,10 13 This inconsistency obscures the true therapeutic value of omega-3 polyunsaturated fatty acids and suggests the presence of key effect-modifying factors.”
Lee, C.-H., Fu, Y., Yang, S.-J., & Chi, C.-C. (2020) · Nutrients · doi:10.3390/nu12092769 · Cited by 139
Jańczyk, W., Lebensztejn, D. M., Wierzbicka, A., Mazur, A., Neuhoff-Murawska, J., Matusik, P., & Socha, P. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.01.056 · Cited by 132
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Lu, W., Li, S., Li, J., Wang, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., et al. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/1459790 · Cited by 123 · cited 1×
“29,49 For NAFD patients with concomitant diabetes, no relevant meta-analysis literature was identified at present, and our meta-analysis included only two articles.”
Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.003 · Cited by 118 · cited 2×
“9,10 13 This inconsistency obscures the true therapeutic value of omega-3 polyunsaturated fatty acids and suggests the presence of key effect-modifying factors.”
Chen, L.-H., Wang, Y.-F., Xu, Q.-H., & Chen, S.-S. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.009 · Cited by 72
Larter, C. Z., Yeh, M. M., Cheng, J., Williams, J., Brown, S., Dela Pena, A., Bell‐Anderson, K. S., & Farrell, G. C. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05157.x · Cited by 70
Musazadeh, V., Dehghan, P., & Khoshbaten, M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002297 · Cited by 45
Lytle, K. A., Depner, C. M., Wong, C. P., & Jump, D. B. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061275 · Cited by 45 · cited 2×
“Statistical heterogeneity was quantified using Cochran’s Q test (P 0.10) and the I² statistic.”
InfluentialMusazadeh, V., Karimi, A., Malekahmadi, M., Ahrabi, S. S., & Dehghan, P. (2023) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13750 · Cited by 44
Sugiyama, E., Ishikawa, Y., Li, Y., Kagai, T., Nobayashi, M., Tanaka, N., Kamijo, Y., Yokoyama, S., Hara, A., & Aoyama, T. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.04.011 · Cited by 43 · cited 1×
“40,41 The lack of effects on ALT, HDL, and LDL may reflect the selective action of omega-3 fatty acids.”
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34 · cited 1×
“44,45 ALT levels exhibit spontaneous fluctuations and may not respond significantly to short-term intervention.”
Climax, J., Newsome, P. N., Hamza, M., Weissbach, M., Coughlan, D., Sattar, N., McGuire, D. K., & Bhatt, D. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016334 · Cited by 26
Kim, S. J., Cho, S. H., & Yun, J. M. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.05.013 · Cited by 24 · cited 1×
“50 This inconsistency may stem from differences in study population characteristics, omega-3 formulation type (EPA/DHA ratio), or baseline MASLD severity.”
Khorshidi, M., Hazaveh, Z. S., Alimohammadi-kamalabadi, M., Jamshidi, S., Moghaddam, O. M., Olang, B., Hatefi, S., Hosseini, A., Jamilian, P., Zarezadeh, M., et al. (2023) · Nutrition Journal · doi:10.1186/s12937-022-00826-5 · Cited by 22 · cited 1×
“48 The studies included in this meta-analysis exhibited differences in these factors, which may explain why no significant overall effect on the aforementioned indicators was detected.”
Moore, E., Patanwala, I., Jafari, A., Davies, I. G., Kirwan, R., Newson, L., Mazidi, M., & Lane, K. E. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad054 · Cited by 21 · cited 1×
“30 These findings suggest that the potential role of omega-3 fatty acids in MASLD may not be universal but rather influenced by underlying metabolic states, with the specific mechanisms requiring comprehensive elucidation.”
Shojasaadat, F., Ayremlou, P., Hashemi, A., Mehdizadeh, A., & Zarrin, R. (2019) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_282_18 · Cited by 16
Orang, Z., Mozaffari–Khosravi, H., Sivandzadeh, G., & Pantović, A. (2019) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-180265 · Cited by 5
Research works printed but not linked: 1
- Tetri, 2008, Am J Physiol Gastr Liver Physiol, 295, G987
Metadata
- Authors
- Li, L., Cong, C., Zhang, X., & Zhang, X.
- Affiliations
- Shandong University of Traditional Chinese Medicine (CN)
- Corresponding author
- Zhang, Xiaoxia
- ORCID
- Li, Lan
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2026-01
- Volume
- Volume 19
- Pages
- 1-14
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC13007540
- OpenAlex
- W7125436140
- Cited by
- 0
- References
- 50
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- omega-3 fatty acids, polyunsaturated fatty acids, triglycerides, non-alcoholic fatty liver disease, type 2 diabetes, triglyceride lowering, dietary supplementation, subgroup analysis, ALT, HDL cholesterol, LDL cholesterol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.